Keyword: biopharmaceuticals

News

Merck Serono and Illumina in Oncology Diagnostics Pact

11.03.2015 - Merck Serono, the biopharmaceutical business of Germany's Merck KGaA, and US biotechnology company Illumina, based at San Diego, California, plan to collaborate on expanding the...

News

Arrowhead Buys Novartis’ RNAi R&D Portfolio

09.03.2015 - California-based Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, has acquired Novartis' entire RNAi research and development...

News

XL-protein Licenses Technology to MSD

16.02.2015 - XL-protein Germany, a privately owned biopharmaceutical company, has licensed its proprietary PASylation technology to MSD Animal Health for development of biopharmaceuticals for...

News

Lonza and Tigenix Sign Toll Manufacture Agreement

13.02.2015 - Swiss fine and specialty chemicals producer Lonza has signed a toll manufacturing agreement with TiGenix, an advanced biopharmaceutical company focused on developing and...

Strategy & Management

Discovering the Future of Pharma

30.09.2014 - Dramatic changes to the scientific and business environments have made it impossible for pharmaceutical companies to continue operating as they have in the past. A perceived...

News

Merck Serono and Mersana Collaborate on Antibody Drug Conjugates

25.06.2014 - Merck Serono, the biopharmaceutical division of Germany's Merck KGaA, and US company Mersana Therapeutics, based in Cambridge, Massachusetts, have agreed to collaborate on...

Plant Construction & Process Technology

Preparing for Tomorrow’s Pharmaceutical Challenges

08.06.2014 - The pharmerging markets will still be extending their progress by 10 to 13%, as population increases and rising incomes contribute to dramatically higher use of medicines. Improved...

Plant Construction & Process Technology

Preparing for Tomorrow’s Pharmaceutical Challenges

09.05.2014 - New legislation, expiring patents and increasing healthcare costs call for decisive changes in the global pharmaceutical industry. New markets for specialty medicines...